147 related articles for article (PubMed ID: 21838147)
1. [Primary drug resistance/sensitivity in vitro and clininical outcome in ovarian cancer patients].
Sedláková I; Tosner J; Cervinka M; Brigulová K; Rezác A; Spacek J; Laco J; Skapinec P
Ceska Gynekol; 2011 Jun; 76(3):184-9. PubMed ID: 21838147
[TBL] [Abstract][Full Text] [Related]
2. [Resistance/sensitivity in vitro in ovarian cancer patients].
Sedláková I; Tosner J; Rezác A; Cervinka M; Brigulová K; Spacek J; Tomsová M; Skapinec P
Ceska Gynekol; 2010 May; 75(3):182-7. PubMed ID: 20731297
[TBL] [Abstract][Full Text] [Related]
3. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
4. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
5. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
6. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
Qian XL; Peng ZL; Liu SL
Ai Zheng; 2003 Dec; 22(12):1352-4. PubMed ID: 14693068
[TBL] [Abstract][Full Text] [Related]
7. [Chemoresistance/Chemosensitivity of ovarian cancer--a case report].
Sedláková I; Tosner J; Rezác A; Cervinka M; Tomsová M; Spacek J
Ceska Gynekol; 2008 Jun; 73(3):140-3. PubMed ID: 18646664
[TBL] [Abstract][Full Text] [Related]
8. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
[TBL] [Abstract][Full Text] [Related]
9. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
[TBL] [Abstract][Full Text] [Related]
10. Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.
Hoskins P; Vergote I; Cervantes A; Tu D; Stuart G; Zola P; Poveda A; Provencher D; Katsaros D; Ojeda B; Ghatage P; Grimshaw R; Casado A; Elit L; Mendiola C; Sugimoto A; D'Hondt V; Oza A; Germa JR; Roy M; Brotto L; Chen D; Eisenhauer EA
J Natl Cancer Inst; 2010 Oct; 102(20):1547-56. PubMed ID: 20937992
[TBL] [Abstract][Full Text] [Related]
11. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
12. Chemoresistance testing of human ovarian cancer cells and its in vitro model.
Brigulová K; Cervinka M; Tošner J; Sedláková I
Toxicol In Vitro; 2010 Dec; 24(8):2108-15. PubMed ID: 20736059
[TBL] [Abstract][Full Text] [Related]
13. [Drug resistance proteins LRP, Pgp, MRP1, MRP3 and MRP5 in ovarian cancer patients].
Sedláková I; Laco J; Tošner J; Spaček J; Cermáková E
Ceska Gynekol; 2013 Dec; 78(6):545-53. PubMed ID: 24372433
[TBL] [Abstract][Full Text] [Related]
14. In vitro chemosensitivity assay of ascites in epithelial ovarian cancer.
Xu X; Dai H; Zhao Y; Wang Y; Xu X; Qian Z; Chen X
Eur J Gynaecol Oncol; 2013; 34(6):559-64. PubMed ID: 24601052
[TBL] [Abstract][Full Text] [Related]
15. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
Matsuo K; Bond VK; Im DD; Rosenshein NB
Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949
[TBL] [Abstract][Full Text] [Related]
16. Apoptosis-based evaluation of chemosensitivity in ovarian cancer patients.
Flick MB; O'Malley D; Rutherford T; Rodov S; Kamsteeg M; Hao XY; Schwartz P; Kacinski BM; Mor G
J Soc Gynecol Investig; 2004 May; 11(4):252-9. PubMed ID: 15120700
[TBL] [Abstract][Full Text] [Related]
17. [A prospective study of adenosine triphosphate-tumor chemosensitivity assay directed chemotherapy in patients with recurrent ovarian cancer].
Gao YT; Wu LY; Zhang W; Zhao D; Li N; Tian HM; Wang XB; Li M; Sun YC; Li N; Li XG
Zhonghua Fu Chan Ke Za Zhi; 2013 May; 48(5):358-63. PubMed ID: 24016479
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of low-dose topotecan in second-line treatment for patients with epithelial ovarian carcinoma.
Gronlund B; Hansen HH; Høgdall C; Engelholm SA
Cancer; 2002 Oct; 95(8):1656-62. PubMed ID: 12365013
[TBL] [Abstract][Full Text] [Related]
19. Predicting resistance to platinum-containing chemotherapy with the ATP tumor chemosensitivity assay in primary ovarian cancer.
Neubauer H; Stefanova M; Solomayer E; Meisner C; Zwirner M; Wallwiener D; Fehm T
Anticancer Res; 2008; 28(2A):949-55. PubMed ID: 18507041
[TBL] [Abstract][Full Text] [Related]
20. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
